Incyte Corporation (INCY) is currently priced at $94, showing a decrease of $1.73 (-1.8%) from the previous close of $95.72. Trading volume stands at $996,644, 60.3% above the average. The asset is experiencing a slight downturn in today's session.
INCY's latest quarterly earnings report, released on Monday, April 27th, revealed a consensus estimate EPS of 1.36. Further details on revenue and profit margin are awaited.
Operating cash flow for INCY is $543.30 million, with a net change in cash of $642.81 million. Cash at the end of the period is reported at $3 billion, reflecting a healthy financial position.
Revenue for INCY amounts to $1.51 billion, generating a gross profit of $1.37 billion. The company posted a net income of $299.28 million, resulting in an EPS of $1.52.
Key financial metrics for INCY include a net profit margin of 19.86%, return on equity of 5.79%, and a price-to-earnings ratio of 16.29. These ratios indicate a mixed performance in profitability and valuation.
INCY's balance sheet shows total assets of $6.96 billion, with cash and cash equivalents amounting to $3 billion. The company maintains a strong position with total liabilities at $1.80 billion.
This real-time financial report offers insights into INCY's performance, highlighting key financial aspects for investors to consider.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.